Investigators Testing Ways To Overcome Gleevec Resistance: High Dose, New Drugs
FDA Approves Abraxane For Second-Line Treatment Of Metastatic Breast Cancer
New Regimens May Benefit Multiple Myeloma Patients
Two New Modalities Promising For Relapsed/Refractory NHL
Amgen’s Kepivance Approved For Severe Oral Mucositis
Clolar Approved for Pediatric Refractory/Relapsed ALL
Blacks Half As Likely To Get Surgery For Esophageal Cancer
NCI-Approved Clinical Trials Listed For January
Trending Stories
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - In The Headlines: Increasing incidence of early-onset cancer is “a paradigm shift oncology isn’t quite prepared for”
- George Sigounas named the first-ever chief science advisor at NCI
- The Directors: Candace Johnson and Jonathan Friedberg on living through uncertainty at NCI, payment woes
Directors of two neighboring cancer centers in Upstate New York will face challenges, but “we’ll get through it” - Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State